Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026

Lifecore Biomedical (NASDAQ: LFCR) will report financial results for its second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens.

Rhea-AI Summary

Lifecore Biomedical (NASDAQ: LFCR) will report financial results for its second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens.

Senior management will host a webcast at 8:00 a.m. Eastern Time, accessible live and on-demand for 30 days via the Investor Events & Presentations page on the company’s website.

Argus Jul 30 session

+0.93% close to close Open Argus

Details

News Market Reaction – LFCR

In the Jul 30 session, LFCR gained 0.93%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

LFCR's two prior earnings-date notices generated +2.63% and -1.15% 24-hour reactions, a mixed record...

Analysis

LFCR's two prior earnings-date notices generated +2.63% and -1.15% 24-hour reactions, a mixed record. The current announcement sets timing, not results; the unresolved risk is whether reported performance changes the platform's prior earnings pattern.

Key Figures

Reporting Date: August 5, 2026 Quarter End: June 30, 2026 Webcast Time: 8:00 a.m. Eastern +1 more

Reporting Date

August 5, 2026

Second-quarter 2026 financial results

Quarter End

June 30, 2026

Second quarter 2026

Webcast Time

8:00 a.m. Eastern

August 5, 2026 results webcast

Archive Availability

30 days

Archived webcast availability

Previous Earnings date Reports

2 past events · Latest: Apr 29

Same Type 2 events

1. Apr 29

   Q1 earnings date

   24h Move

   +2.6%

   Q1 financial results announcement scheduled before market open

2. Mar 09

   Q4 earnings date

   24h Move

   -1.1%

   Fourth-quarter and transition-period results announcement scheduled before market open

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cdmo, fill and finish, hyaluronic acid

3 terms

cdmo technical

"contract development and manufacturing organization (“CDMO”)"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

fill and finish technical

"capabilities in the development, fill and finish of sterile injectable"

The final stage of producing biological medicines where bulk drug substance is transferred into final dosage forms—filling vials, syringes, or cartridges—and then sealed, labeled and packaged for distribution. It matters to investors because this step determines how quickly a treatment can reach patients, creates manufacturing bottlenecks or capacity value, and often involves specialized facilities and regulatory controls; think of it as the bottling and labeling line in a beverage plant that readies product for sale.

hyaluronic acid medical

"manufacturer of premium, injectable-grade hyaluronic acid"

A naturally occurring molecule that acts like a tiny sponge, holding water in skin, joints and eyes to keep tissues plump and lubricated. Investors track products containing hyaluronic acid because they power large markets—such as skincare, injectable fillers, eye drops and wound treatments—so demand, regulatory approvals, manufacturing capacity and raw-material costs can meaningfully affect a company’s sales and profit outlook.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Webcast Scheduled for Wednesday, August 5 at 8:00 a.m. Eastern

CHASKA, Minn., July 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens. At 8:00 a.m. Eastern Time that day, members of Lifecore’s senior management team will host a webcast to discuss the results.

To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore’s website at: https://ir.lifecore.com/events-presentations. Following the live webcast, an archived version of the webcast will be available on the company’s website for 30 days.

About Lifecore Biomedical 
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated injectables contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Lifecore Biomedical, Inc. Contact Information:

Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
sdiaz@vidasp.com

Jennifer Arcure (Media)
917-603-0681 
jarcure@vidasp.com

Lifecore Biomedical
Ryan D. Lake (CFO)
952-368-6244
ryan.lake@lifecore.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Lifecore Biomedical (NASDAQ: LFCR) report Q2 2026 earnings?

Lifecore Biomedical will report financial results for its second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens. According to Lifecore, the release will precede a management webcast that morning.

What time is Lifecore Biomedical’s Q2 2026 earnings webcast on August 5, 2026?

Lifecore Biomedical’s Q2 2026 webcast is scheduled for 8:00 a.m. Eastern Time on August 5, 2026. According to Lifecore, senior management will discuss the quarterly results during this live online event.

How can investors access Lifecore Biomedical’s (LFCR) Q2 2026 earnings webcast?

Investors can access Lifecore Biomedical’s Q2 2026 webcast via the Investor Events & Presentations page on the company’s website. According to Lifecore, this page will host both the live and archived webcast streams.

Will a replay of Lifecore Biomedical’s August 5, 2026 earnings webcast be available?

Yes, a replay will be available. According to Lifecore, an archived version of the August 5, 2026 webcast will be accessible on the company’s website for 30 days following the live presentation.

What does Lifecore Biomedical do as an injectables CDMO (NASDAQ: LFCR)?

Lifecore Biomedical is a fully integrated injectables contract development and manufacturing organization. According to Lifecore, it develops and performs fill-finish of sterile injectable products and manufactures injectable-grade hyaluronic acid for biopharmaceutical partners.

Where can I find more investor information about Lifecore Biomedical (LFCR)?

Investor information is available on Lifecore Biomedical’s website, including the Investor Events & Presentations section. According to Lifecore, this area hosts webcasts, presentations, and related financial communications for shareholders and analysts.